MedTrace Logo

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

NCT05614453 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the effect of the combination treatment of sitravatinib with tislelizumab in patients with Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy.

The main question it aims to answer is the percentage of people in the study who have a partial or complete response to the treatment.

Participants will receive treatment under the care of their treating physician and will be reviewed regularly.

Conditions

  • Metastatic Cervical Cancer

Interventions

DRUG

Tislelizumab

Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.

DRUG

Sitravatinib

Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.

Sponsors & Collaborators

  • BeiGene

    collaborator INDUSTRY

  • Australia New Zealand Gynaecological Oncology Group

    lead OTHER

Principal Investigators

  • Jeff Goh, MBBS, FRACP · Royal Brisbane & Womens Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2023-06-30
Completion
2023-06-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05614453 on ClinicalTrials.gov